Bioethics includes every ethical question linking and pertaining to medicine and the health of living things. Everything from all aspects of nursing to euthanasia to pain killers, and from the arguments about abortion to the law of malpractice is included when using the term bioethics. Bioethics is a wide-ranging, very broad category of ethics. The issue of bio-ethics presents numerous new dilemmas. The majority of these issues stem from the introduction of new, genetically-engineered organisms. These organisms, or at least many of them, are created in laboratories, by cloning and gene modification. Scientists are creating these organisms as they want them all while causing controversy.
The bioethical industry consists of a group of small start-up companies, mainly funded by capital money and other gainful corporations. Biotechnology was first created by these companies because most of the bigger, more established science and pharmaceutical corporations thought that biotechnology would never be successful. The bigger pharmaceutical corporations did not capitalize in technology in the beginning. Together with scientists started the bulk of biotech corporations, and as a result, a lot of what was traditional in the pharmaceutical business has been transformed. This happens often when new people and new technology are brought about especially in today’s industry. In more advanced countries where genetically engineered disputes may arise, the developments have total protection through exclusive rights and other supervisory agencies. These issues arise from identification of the newfound bioengineered organisms, and this approach allows the engineering and entrepreneurs to recuperate from the immense costs involved in the research and development of genetic engineering. It endorses the development of products to profit society, and it permits access for a greater genetic bank for studies, testing, and exploration. There is an additional side to all of this where the scientists can set an extreme price for their product while excluding any rivalry for a particular period of time. It allows for duplicates of living things to be prepared simply and economically. This only happens outside the United States, where stringent guidelines are not used. No nations spend any financial amount equal to the over 300 million dollars to use the patent and trademark office, as the United States does. Many nations have the opinion that these genetic products are not intellectual property, and are not subject to the conventional patent laws. They should not belong to society just like any other living organism that has evolved through the natural processes. No matter which aspect of the bioethical issue is being evaluated, the argument continues throughout the field. The amounts of these problems keeps rising as science advances; nevertheless, it is not soon that we will see the resolution of a very small percentage of these problems regardless of the continuously changing amount of them. Whenever a new medicine or technology is developed for use in the health care community, bioethical questions are raised and answers are demanded and debated, and hopefully answered eventually. In past months, there has been much heated debate over many issues that bioethics encompass.